Pitt Shield

Focused ultrasound-mediated blood-brain barrier opening combined with magnetic targeting cytomembrane based biomimetic microbubbles for glioblastoma therapy.

Authors: He C, Wu Z, Zhuang M, Li X, Xue S, Xu S, Xu J, Wu Z, Lu M

Glioblastoma is the most common type of brain tumor. Due to the presence of the blood-brain barrier, the effects of chemotherapy have been unsatisfactory. The combination of focused ultrasound and microbubbles to reversibly open the blood-brain barrier is now considered a key factor in improving treatment outcomes of glioblastoma. In this study, we developed bionic drug delivery microbubbles, which in combination with focused ultrasound had an obvious inhibitory effect on glioblastoma. We extracted the brain microvascular cell membranes, combined them with lipid components, and loaded them with superparamagnetic iron oxide and doxorubicin to prepare biomimetic drug delivery microbubbles (FeDOX@cellMBs). We demonstrated that FeDOX@cellMBs retained the intrinsic properties of loading, such as magnetic properties and drug toxicity, both in vitro and in vivo. FeDOX@cellMBs exhibited good tumor targeting and uptake under the combined action of magnetic and focused ultrasound. Importantly, the FeDOX@cellMBs demonstrated excellent internal stability and effectively inhibited tumor growth in orthotopic glioblastoma mice. Finally, organ H&E staining confirmed that FeDOX@cellMBs were safe for use. In conclusion, FeDOX@cellMBs successfully penetrated the blood-brain barrier and effectively inhibited glioblastoma growth under the combined effects of focused ultrasound and magnetic stimulation. These results provide a new approach for the treatment of glioblastoma, with implications for future clinical translation.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To develop and evaluate biomimetic, SPIO- and doxorubicin-loaded microbubbles (FeDOX@cellMBs) that, when combined with focused ultrasound and magnetic targeting, can penetrate the blood-brain barrier and effectively inhibit glioblastoma.
Animal model / Human subject Mus musculus, C57BL/6, 6–8 weeks, female
Disease model glioblastoma
MRI or image guidance method none.
Targeted brain region(s) Glioblastoma Tumor
Cargo name and characteristics FeDOX: superparamagnetic iron oxide nanoparticles (SPIONs) loaded with doxorubicin (small‑molecule anthracycline chemotherapy) and cloaked with brain microvascular cell membrane–derived lipid coating (biomimetic nanoparticle). Characteristics: magnetically responsive nanoparticle formulation enabling magnetic targeting, retains doxorubicin cytotoxicity, enhanced tumor uptake and blood–brain barrier penetration under combined focused ultrasound and magnetic stimulation, improved internal stability and demonstrated in vivo safety.
Route of administration Intravenous injection of biomimetic microbubbles (FeDOX@cellMBs) combined with focused ultrasound-mediated blood-brain barrier opening and magnetic targeting

Outcomes and Safety

Summary of Outcomes Biomimetic FeDOX@cellMBs combined with focused ultrasound and magnetic guidance opened the blood–brain barrier, enhanced doxorubicin delivery and tumor targeting, increased glioblastoma apoptosis and reduced tumor proliferation/growth in orthotopic mouse models without obvious organ toxicity.
Duration of biological effect 24 h
Safety-related matter H&E staining showed no significant damage to brain, heart, liver, spleen, lungs, or kidneys and the authors report FeDOX@cellMBs exhibited good biological safety, although they note that direct exposure of biomimetic microbubbles to the bloodstream can be biotoxic.

Brain Region

Ultrasound Parameters

Ultrasound instrument none.
FUS Frequency 1.1 MHz
FUS Intensity Not reported in the provided text
FUS Pressure Not reported in the provided text
FUS Mode continuous
Pulse duration Not reported
Duration of a single FUS session Not reported in the provided text
Focal Characteristics none.

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search